Latest News for MEDIF
MediPharm Labs Corp. (LABS:CA) Q4 2025 Earnings Call Transcript
FY 2025 revenue of $45.1 million, an increase of 8% over 2024 International Medical Cannabis revenue increased 43% year-over-year and represented more than 50% of total revenue Increased cash balance of $10.8 Million at the end of Q4, up $0.2 million from Q3 2025 Company remains virtually debt-free, with outright ownership of two production facilities Management to Host Conference Call / Webcast on March 30th, 2026,…
MediPharm Labs will release its financial results for the three & twelve months ended December 31st, 2025, before markets open on Monday, March 30th, 2026.
TORONTO, Jan. 19, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm" or the "Company"), a pharmaceutical company specialized in precision-based cannabinoids, today announced that David Pidduck will be stepping down from his role as the Company's Chief Executive Officer, effective January 23rd, 2026. The Board of Directors (the "Board") has appointed Greg Hunter, the…
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for MEDIF.
Senate Trading
No Senate trades found for MEDIF.
U.S. House Trading
No House trades found for MEDIF.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.